A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

ClinicalTrials.gov ID: NCT03085914

Public ClinicalTrials.gov record NCT03085914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Study identification

NCT ID: NCT03085914
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Incyte Corporation; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Epacadostat Drug
Pembrolizumab Drug
Oxaliplatin Drug
Leucovorin Drug
5-Fluorouracil Drug
Gemcitabine Drug
nab-Paclitaxel Drug
Carboplatin Drug
Paclitaxel Drug
Pemetrexed Drug
Cyclophosphamide Drug
Cisplatin Drug
Investigator's choice of platinum agent Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 1, 2017
Primary completion: Jan 24, 2019
Completion: Jul 12, 2020
Last update posted: Sep 22, 2022

2017 – 2020

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
Mayo Clinic Arizona	Phoenix	Arizona	85054	—
University of California San Diego Medical Center, Moores Cancer Center	La Jolla	California	92093	—
The Angeles Clinic and Research Institute	Los Angeles	California	90025	—
Mayo Clinic	Jacksonville	Florida	32224	—
University of Chicago	Chicago	Illinois	60637	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Carolina Bio-Oncology Institute, PLLC	Huntersville	North Carolina	28078	—
Oregon Health and Science University	Portland	Oregon	97239	—
University of Pennsylvania Health System	Philadelphia	Pennsylvania	19104	—
University of Pittsburgh Cancer Institute	Pittsburgh	Pennsylvania	15237	—
Tennessee Oncology - Nashville; The Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
Vanderbilt University; Henry Joyce Cancer Clinic	Nashville	Tennessee	37232	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Huntsman Cancer Institute at University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03085914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 22, 2022 · Synced Jun 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03085914 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →